Immutep's TACTI-004 Phase III Study in First-Line NSCLC Discontinued Following Futility Analysis.

Immutep announced that the TACTI-004 Phase III study in first-line non-small cell lung cancer will be discontinued following a futility analysis. The Independent Data Monitoring Committee recommended the discontinuation of the trial based on safety and efficacy data. The company will halt enrolment and implement an orderly wind down of the study. Immutep's cash runway is now expected to extend beyond Q2 CY2027. The company will reassess capital allocation priorities once operational assessments and a full analysis of the study data have been finalised.